In the case of the lung, as many as 14% of non-small cell lung cancers acquire resistance to EGFR inhibitors by adopting a small cell lung cancer (SCLC) neuroendocrine-like phenotype (132). This evidence concerns the gene EGFR and small cell lung carcinoma.